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Skeletal muscle cells exhibit an enormous plastic capacity in order to adapt to external
stimuli. Even though our overall understanding of the molecular mechanisms that
underlie phenotypic changes in skeletal muscle cells remains poor, several factors
involved in the regulation and coordination of relevant transcriptional programs have been
identified in recent years. For example, the peroxisome proliferator-activated receptor
γ coactivator-1α (PGC-1α) is a central regulatory nexus in the adaptation of muscle
to endurance training. Intriguingly, PGC-1α integrates numerous signaling pathways
and translates their activity into various transcriptional programs. This selectivity is
in part controlled by differential expression of PGC-1α variants and post-translational
modifications of the PGC-1α protein. PGC-1α-controlled activation of transcriptional
networks subsequently enables a spatio-temporal specification and hence allows a
complex coordination of changes in metabolic and contractile properties, protein
synthesis and degradation rates and other features of trained muscle. In this review,
we discuss recent advances in our understanding of PGC-1α-regulated skeletal muscle
cell plasticity in health and disease.
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INTRODUCTION
Cell plasticity is often controlled by complex transcriptional networks. While traditionally,
much of the research on such networks was focused on transcription factors, the important
role of co-regulators has been increasingly appreciated in recent years (Dasgupta et al., 2014;
Mouchiroud et al., 2014). Co-regulator proteins have no intrinsic DNA-binding domain and
thus rely on transcription factors to be recruited to regulatory elements. The ability of co-
regulators to bind to various partners enables the regulation of broad, complex transcriptional
programs. The peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α)
is a prototypical member of this class of proteins. Initially discovered in a screen comparing
white and brown adipose tissue, expression of PGC-1α has subsequently been documented in
all tissues with a high energetic demand, including brain, kidney, skeletal, and cardiac muscle,
liver, pancreas, or the retina (Martínez-Redondo et al., 2015). The core function of PGC-
1α centers on the induction of mitochondrial biogenesis and oxidative metabolism. PGC-1α
likewise controls highly tissue-specific programs, such as hepatic gluconeogenesis or mitochondrial
uncoupling in brown adipose tissue. Since the phenotype of global PGC-1α transgenic and
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knockout mice is complex (Lin et al., 2004; Liang et al.,
2009), many insights into organ-specific function and regulation
of PGC-1α, including those discussed in this review unless
otherwise stated, have mostly been obtained from murine tissue-
specific gain- and loss-of-function models (Handschin et al.,
2005). In skeletal muscle, specific overexpression of PGC-1α
at physiological levels is sufficient to induce an endurance-
trained phenotype (Lin et al., 2002) while super-physiological
overexpression promotes fiber damage and impaired muscle
function (Lin et al., 2002; Miura et al., 2006). Inversely, ablation
of PGC-1α gene expression in this tissue promotes several typical
signs of pathological inactivity, including a local and systemic
chronic inflammation (Handschin et al., 2007a,b). A reduction
in PGC-1α gene expression in human skeletal muscle has been
associated with insulin resistance and type 2 diabetes, at least
in some patient cohorts (Patti et al., 2003). Of note, mice
with a heterozygous deletion of PGC-1α in skeletal muscle also
exhibit a dysregulation of glucose homeostasis (Handschin et al.,
2007b).
PGC-1α integrates the activity of the major signaling
pathways that are important in a contracting muscle fiber
and accordingly, PGC-1α transcript and protein levels are
elevated after a training bout (Pérez-Schindler and Handschin,
2013). As consequence, PGC-1α then controls the biological
program encompassing all plastic changes of the muscle cell
to endurance exercise. For example, mice with elevated muscle
PGC-1α levels exhibit a higher number of mitochondria, a
switch toward oxidative, slow-twitch muscle fiber types, altered
substrate synthesis and metabolism, and a reduction in muscle
protein breakdown (Handschin, 2010). Importantly, the effects
of PGC-1α extend beyond muscle cells: elevation of PGC-
1α in muscle leads to higher tissue vascularization (Arany
et al., 2008) and a remodeling of the post- and presynaptic
side of the neuromuscular junction (Handschin et al., 2007c;
Arnold et al., 2014). Furthermore, PGC-1α-regulated endocrine
mediators, members of the so-called myokine protein family,
promote beige fat cell differentiation and activation in white
adipose tissue or neurogenesis in the hippocampus and thereby
dramatically extend the reach of muscle PGC-1α (Schnyder
and Handschin, 2015). Surprisingly, while overexpression of
PGC-1α is sufficient to induce an endurance-trained muscle
phenotype, several aspects of training adaptation seem to be
retained even in mice with a global or muscle-specific knockout
of this coactivator, respectively (Leick et al., 2008; Rowe et al.,
2012). Discrepancies in such studies however indicate that the
specific animal model, training type, timing, intensity, and other
aspects of the exercise protocol are important for the assessment
of the requirement of PGC-1α in exercise adaptation (Geng et al.,
2010). Furthermore, these studies imply a redundant regulation
of these evolutionarily extremely important plastic changes in
skeletal muscle in which PGC-1α can be partially replaced by
other, so far unknown regulators. Thus, in a physiological setting,
PGC-1α controls a highly complex transcriptional network that
requires spatial and temporal specification, coordination of
anabolic and catabolic pathways as well as precise activation
and termination. In this mini review, we highlight some of
the recent mechanistic findings that contribute to the ability of
PGC-1α to regulate transcription in such a broad and precise
manner.
INTEGRATION OF
CONTRACTION-INDUCED SIGNALING
PATHWAYS BY PGC-1α IN SKELETAL
MUSCLE
Muscle fiber contraction is linked to activation by the motor
neuron, mechanical stress, relative tissue physoxia, an altered
neuroendocrine milieu, changes in metabolic demand and other
stimuli that engage various signaling pathways. All of these
signals converge on PGC-1α and promote a transcriptional
induction of the gene or induce posttranslational modifications
(PTM) of the protein (Figure 1A), including PGC-1α protein
phosphorylation by various kinases on different phosphorylation
sites, acetylation, methylation, sumoylation, ubiquitination,
and acetylglucosamination (Figure 1B; Fernandez-Marcos and
Auwerx, 2011). The effects of most of these modifications on
PGC-1α function are still poorly understood. Some of the PTMs
can alter the stability of the PGC-1α protein or modulate the
interaction with transcription factors or other co-regulators. For
example, phosphorylation by the p38 mitogen-activated protein
kinase (p38 MAPK) results in a prolongation of the normally
very short half-life of the PGC-1α protein of ∼2.5 h (Puigserver
et al., 2001), at least in part by preventing ubiquitination of
PGC-1α and therefore stabilizing the protein (Olson et al.,
2008). The AMP-dependent protein kinase (AMPK) likewise
phosphorylates the PGC-1α protein in addition to its positive
effect on PGC-1α gene transcription and predominantly triggers
catabolic pathways to rectify a relative energy deficit, e.g., in
exercise (Jager et al., 2007). Such a temporal specification is
extremely important to avoid futile cycles of PGC-1α-controlled
anabolic and catabolic pathways, e.g., fatty acid β-oxidation and
de novo lipogenesis (Summermatter et al., 2010). Moreover,
PTMs could also determine spatial differentiation of PGC-1α
function. For example, the interaction between PGC-1α and
the GA-binding protein (GABP, also called nuclear respiratory
factor 2 or NRF2) not only requires the presence of host
cell factor (HCF) as an additional adaptor protein, but also
specific phosphorylation events both on PGC-1α as well as
the GABPB1 subunit of the GABP complex (Handschin et al.,
2007c). These PTMs can be triggered by motor neuron-
evoked neuregulin stimulation of the muscle fiber and thereby
control a specific transcriptional activation of post-synaptic
neuromuscular junction genes by PGC-1α and GABP exclusively
in sub-synaptic nuclei (Handschin et al., 2007c). Thus, in
addition to the modulation of protein stability, PTMs might alter
the activity and stability of PGC-1α as well as the ability to
interact with transcription factors and thereby regulate specific
transcriptional programs (Handschin and Spiegelman, 2006).
For most modifications of the PGC-1α protein, a “PTM code”
(Lonard and O’malley, 2007) that determines transcription factor
interaction specificity has not been elucidated. A prototypical
example for a PGC-1α PTM code however is provided by
the S6 kinase (S6K)-mediated phosphorylation that selectively
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FIGURE 1 | Complex activation of the transcriptional co-activator PGC-1α by different signaling pathways. (A) Exercise triggers a complex transcriptional
activation as well as various posttranslational modifications to control PGC-1α levels and activity. (B), Posttranslational modifications of the PGC-1α protein. AA, amino
acids; Ac, acetylation; Akt, protein kinase B; AMPK, AMP-activated protein kinase; β2AR, β2 adrenergic receptor; CaMK, Ca2+/calmodulin-dependent protein kinase;
CnA, calcineurin A; Clk2, Cdc2-like kinase 2; CREB, cAMP response element binding protein; ERRα, estrogen-related receptor α; Gsk3β, glycogen synthase kinase 3
beta; HNF4 α, hepatic nuclear factor 4 α; MEF2C/2D, myocyte enhancer factors 2C/D; Me, methylation; mTORC1, mammalian target of rapamycin complex 1;
OGlNa, O-linked β-N-acetylglucosamination; OGT, O-linked β-N-acetylglucosamine transferase; p38 MAPK, p38 mitogen-activated protein kinase; PI3K,
phosphoinositide 3 kinase; PKA, protein kinase A; P, phosphorylation; PPARα, peroxisome proliferator-activated receptor α; PRMT1, protein arginine
methyltransferase 1; RIP140, receptor interacting protein 140; RNF34, ring finger protein 34; S6K, S6-kinase; SCFFwb7/Cdc4, SCF ubiquitin ligase complex subunit
Fwb7/Cdc4; SIRT1, sirtuin-1; Su, sumoylation; Sumo1, small ubiquitin related modifier 1; Ubi, ubiquitination; YY1, yin yang 1.
retains the ability of PGC-1α to boost fatty acid oxidation
and mitochondrial function while attenuating its effect on
gluconeogenesis in the liver (Lustig et al., 2011). Mechanistically,
these PTMs reduce the interaction between PGC-1α and the
hepatic nuclear factor 4 α (HNF4α), but not co-activation of the
estrogen-related receptor α (ERRα) or PPARα. In addition to
binding to transcription factors, PTMs of the PGC-1α protein can
also affect the interaction with other co-regulators. For example,
the co-repressors p160 myb binding protein (p160MBP) and
receptor interacting protein 140 (RIP140) are recruited to PGC-
1α in a PTM-dependent manner: p160MBP inhibits the ability
of PGC-1α to regulate mitochondrial gene expression in the
absence of p38 MAPK-mediated phosphorylation (Fan et al.,
2004) while RIP140 associates with and represses sumoylated
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PGC-1α (Rytinki and Palvimo, 2009). Other co-repressors reduce
PGC-1α activity by competing for binding to transcription
factors, for example modulation of ERRα co-activation by the
nuclear receptor co-repressor 1 (NCoR1; Pérez-Schindler et al.,
2012) or of the glucocorticoid receptor by the small heterodimer
partner (SHP; Borgius et al., 2002). PTM-dependent binding
events are also observed for co-activators as exemplified by the
interaction of PGC-1α with the Mediator 1 (MED1) subunit
of the TRAP/DRIP/mediator complex that is disrupted after
phosphorylation of PGC-1α by the Cdc2-like kinase 2 (Clk2;
Tabata et al., 2014). Ubiquitination and subsequent proteasomal
degradation of the PGC-1α protein form a negative feedback loop
to ensure timely termination of the PGC-1α response (Sano et al.,
2007). This process might be triggered by PGC-1α protein self-
aggregation upon reaching a critical threshold (Sano et al., 2007).
Thus, PGC-1α serves as recipient of amultitude of PTMs, thereby
integrates the activity of the respective signaling pathways and
subsequently triggers a transcriptional response that is adapted
to the specific cellular context.
REGULATORY AND FUNCTIONAL
DIVERSITY BASED ON THE PGC-1α GENE
STRUCTURE AND TRANSCRIPT VARIANTS
PGC-1α gene expression is rapidly and robustly increased in
response to external stimuli that increase the energy demand
such as cold in brown fat, fasting in the liver, or contraction in
skeletal muscle (Lin et al., 2005). The cAMP response element
binding protein (CREB) and the activating transcription factor-
2 (ATF-2), both of which bind to cAMP response elements
(CRE), are common regulators of PGC-1α transcription in most
tissues. In addition, tissue-specific transcription factors provide
an additional layer of control, e.g., myocyte enhancer factors
2C/D (MEF2C and -2D) in muscle cells (Pérez-Schindler and
Handschin, 2013). A positive autoregulatory loop of MEF2C/D
co-activation by PGC-1α on its own promoter furthermore
contributes to adequate and controlled induction of PGC-1α
transcription in this tissue (Handschin et al., 2003). Intriguingly,
this theme of using cross- and autoregulatory loops, thus forming
biological switches, is also observed in early downstream target
gene regulation, for example in the induction of ERRα and
GABPA by PGC-1α (Mootha et al., 2004).
PGC-1α transcription can be initiated from three start sites on
two alternative promoters. Moreover, alternative RNA processing
further increases the number of PGC-1α transcripts and, as a
consequence, protein variants (Martínez-Redondo et al., 2015).
Even though the regulatory elements of the two promoters
have not yet been studied in detail, the proximal promoter
seems to provide a more robust basal expression while the
distal promoter that is approximately 13 kb upstream exhibits
a higher dynamic range in gene expression, at least in skeletal
muscle (Martínez-Redondo et al., 2015). It is still unclear whether
alternative promoter usage is closely linked to the transcription
of PGC-1α isoforms. Moreover, the functional consequence of
the selective expression of most PGC-1α transcript variants is
unknown. Surprisingly however, the PGC-1α4 variant seems to
regulate a highly distinct transcriptional program with very little
overlap compared to that of the other variants (Ruas et al.,
2012). PGC-1α 4 contributes to skeletal muscle adaptation to
resistance training and the ensuing fiber hypertrophy (Ruas et al.,
2012), at least in certain contexts (Pérez-Schindler et al., 2013),
diametrically opposite to the endurance exercise-like phenotype
triggered by the other PGC-1α isoforms. In humans however,
some studies questioned an exclusive correlation between PGC-
1α4 expression and resistance training (Lundberg et al., 2014)
warranting further studies. In any case however, the gene
structure and transcript processing of PGC-1α thus provide
an additional layer of regulatory and functional specification
(Handschin and Spiegelman, 2006).
PGC-1α-CONTROLLED
TRANSCRIPTIONAL NETWORK
REGULATION ALLOWS
CONTEXT-DEPENDENT CONTROL AND
SPECIFICATION
Originally, PGC-1α has been discovered as a coactivator of
PPARγ and was hence named accordingly (Puigserver et al.,
1998). It however became clear that PGC-1α not only interacts
with this, but also a number of other nuclear receptors and
non-nuclear receptor transcription factors. Intriguingly, these
interactions are mediated by different structural domains within
the PGC-1α protein, with a more N-terminal preference for
nuclear receptor co-activation while others, for example MEF2
or forkhead box protein 1 (Foxo1) bind PGC-1α closer to
the C-terminus (Lin et al., 2005). Therefore, the functional
specificity of PGC-1α isoforms that lack certain domains of
the full-length protein could stem from the specific ablation
and enhancement of binding to transcription factor partners
(Handschin and Spiegelman, 2006; Martínez-Redondo et al.,
2015). Despite the identification of various interaction partners,
PGC-1α seems to have a special relationship with ERRα, at least
in the regulation of mitochondrial genes (Mootha et al., 2004).
ERRα is an orphan nuclear receptor that is mainly activated
by co-activator binding in a ligand-independent manner (Kallen
et al., 2004). Moreover, PGC-1α rapidly induces the transcription
of ERRα as an early response target gene (Mootha et al., 2004).
It thus is not surprising that pharmacological inhibition of the
interaction between PGC-1α and ERRα or knockdown of ERRα
has a potent effect on many PGC-1α target genes in muscle
cells (Mootha et al., 2004; Schreiber et al., 2004). A global
analysis of PGC-1α recruitment to regulatory elements in the
mouse genome combined with an expression analysis however
revealed a so-far largely underestimated number of putative
transcription factor partners beyond ERRα to be involved in
PGC-1α-mediated target gene regulation in muscle cells (Baresic
et al., 2014). Furthermore, transcription factor motif activity
response analysis not only predicts ERRα to be involved in the
regulation of primary, but also secondary PGC-1α target genes,
thus both in the co-activated state but also working without PGC-
1α in this context. These data indicate a much higher complexity
of transcription factor engagement by PGC-1α than previously
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suggested. Second, the combination of PGC-1α ChIPseq and
gene expression data revealed that of the high number of PGC-
1α repressed genes, only a small minority, ∼5%, have a PGC-
1α DNA recruitment peak within a distance of ±10 kb of their
promoter. Accordingly, the findings imply that the effect of PGC-
1α on gene repression is predominantly indirect and that PGC-1α
lacks an intrinsic inhibitory function (Baresic et al., 2014). While
a systematic analysis of gene repression by PGC-1α remains
to be done, PGC-1α-dependent reduction of the activating
phosphorylation of the p65 subunit of the nuclear factor κB
(NF-κB; Eisele et al., 2013) could account for at least some of
the indirect inhibitory effect of PGC-1α on pro-inflammatory
muscle gene expression (Eisele and Handschin, 2014). Third, this
systematic study revealed novel insights into themechanisms that
ensure functional redundancy and complementation of PGC-1α-
mediated transcriptional control. Principal component analysis
of the transcription factor binding motifs within the regions of
PGC-1α DNA recruitment implied an important role for the
activator protein-1 (AP-1) transcription factor complex in PGC-
1α-controlled gene expression (Baresic et al., 2014). AP-1 is a
well-studied stress response gene in various cellular contexts,
but has so far never been associated with PGC-1α function
in muscle. Interestingly, the group of direct targets for AP-1
and PGC-1α was significantly enriched in genes associated with
the cellular response to hypoxia, including several regulators
of vascularization. This regulation complements the previously
discovered control of the expression of the vascular endothelial
growth factor (VEGF) by PGC-1α and ERRα (Arany et al.,
2008). These findings imply that this seemingly redundant
usage of different transcription factors to regulate the same
biological program ensures adequate regulation of this critical
process. Alternatively, the ability of PGC-1α to enhance the
transcriptional activity of different partners might also indicate
that PGC-1α is able to regulate the respective target genes
in different cellular contexts, e.g., by binding to ERRα in a
metabolically stressed muscle cell and acting together with AP-1
upon reduced physoxic conditions (Figure 2). Exercise triggers
a hypoxic response including an activation of the hypoxia-
inducible factor-1 (HIF-1) in muscle cells by a lowering of the
relative tissue oxygen availability due to a dysbalance between
oxygen consumption and supply, exacerbated by contraction-
mediated constriction of blood vessels (Lindholm and Rundqvist,
2015). Together, the current data highlight the vast complexity
of diverse mechanisms by which PGC-1α exerts a pleiotropic
response in muscle cells.
CONCLUSIONS AND OUTLOOK
In essence, PGC-1α is a protein docking platform that on one
side is recruited to transcription factors bound to their target
gene promoters and enhancers, and on the other side interacts
with components of the histone acetyltransferase (Puigserver
et al., 1999), TRAP/DRIP/mediator (Wallberg et al., 2003),
and SWI/SNF (Li et al., 2008) co-regulator protein complexes.
Thereby, PGC-1α greatly boosts transcription even though
PGC-1α lacks any discernable intrinsic enzymatic activity.
Despite this ostensible simplicity in function, PGC-1α can
FIGURE 2 | PGC-1α engages different transcription factors to robustly
regulate biological programs. Co-activation of the estrogen-related
receptor α (ERRα) and the activator protein-1 transcription factor complex
(AP-1) allow a differential regulation of the gene program for vascularization,
cytoprotection, and hypoxia response triggered by different stimuli, e.g., a
change in the metabolic demand and the ensuing angiogenesis to improve
substrate availability or neovascularization as a response to a
contraction-mediated reduction in tissue physoxia and an ensuing
re-oxygenation for adequate oxygen supply. SPP1, secreted phosphoprotein
1; VEGF, vascular endothelial growth factor.
control highly complex transcriptional programs in various
tissues with a significant impact on organ plasticity. The
ability of PGC-1α to integrate different signaling pathways
through a multitude of PTMs, selective activation of alternative
promoters and expression of transcript variants could provide
a mechanistic explanation for the key regulatory function of
PGC-1α in the regulation of tissue phenotypes. However, more
studies will be required to obtain a better understanding and
overview on the different aspects of the regulation of a co-
activator-controlled transcriptional network, which not only is
of high interest to understand the basic biology, but could
also have a significant clinical impact. In a physiological and
pathophysiological context, elevation of PGC-1α in muscle
promotes a high endurance phenotype and ameliorates various
muscle diseases with different etiologies, including Duchenne
muscular dystrophy (Handschin et al., 2007c), denervation-
induced fiber atrophy (Sandri et al., 2006), or sarcopenia (Wenz
et al., 2014), respectively. To date, it is not clear which functions
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of muscle PGC-1α are responsible for such a broad therapeutic
effect (Handschin, 2009). Similarly, pharmacological agents that
robustly, specifically and safely elevate PGC-1α in skeletal muscle
in the desired therapeutic window remain elusive (Svensson
and Handschin, 2014). Finally, based on studies with muscle-
specific PGC-1α transgenic animals that have an accelerated
development of insulin resistance on a high fat diet (Choi
et al., 2008), which can only be rectified by bona fide physical
activity (Summermatter et al., 2013), the application of so-
called “exercise mimetics,” compounds that elicit exercise-like
effects in muscle and other tissues, might be problematic.
Therefore, to design partial exercise mimetics or new compounds
that specifically activate certain functions of PGC-1α, better
knowledge about upstream regulators and downstream effects
on the transcriptional network are needed. In particular, even
though a strong correlation between muscle PGC-1α expression,
exercise, and diseases states has been repeatedly documented in
humans (e.g., see Silvennoinen et al., 2015), information about
the regulation and function of human muscle PGC-1α so far
remains largely descriptive. Until further insights are obtained,
physical activity thus remains a cheap and effective way for the
prevention and treatment of many chronic diseases (Handschin
and Spiegelman, 2008), at least in exercise-tolerant patients.
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